Chugai Pharmaceutical signed an agreement with EpiVax to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox. Read the full story
Tag Archive | "drug development"
Licensing agreement for ISPRI and Optimatrix platform for de-risking biologics
Posted on 31 October 2014
